Murine spontaneous T‐cell leukemia constitutively expressing IL‐2 receptor—a model for human T‐cell malignancies expressing IL‐2 receptor

Hefziba Lugasi*, Silvia Hajos, John R. Murphy, Terry B. Strom, Jean Nichols, Carlos Peñarroja, David Naor

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

28 Scopus citations

Abstract

We describe a new, spontaneously occurring BALB/c‐derived murine T‐cell leukemia. The leukemic cells, designated LB, grow rapidly and progressively in the syngeneic host with no signs of effective immunological resistance. LB cells expressed the Thy‐1+, Lyt‐2+, L3T4, CD3 class‐1+, CD25+ (IL‐2 receptor, IL‐2R), class‐II, gp70 phenotype. As LB cells express IL‐2, as indicated by staining with 2 distinct anti‐CD25 IL‐2R monoclonal antibodies (MAbs), the therapeutic efficacy of IL‐2‐diphtheria toxin‐related protein was tested on this leukemic model. IL‐2‐diphtheria toxin, but not diphtheria toxin, efficiently inhibited the proliferation of LB cells. The proliferation of a murine myeloma cell line, which does not express IL‐2R, was not inhibited by IL‐2‐diphtheria toxin. The possible implantation of this animal model in fundamental and practical studies is discussed.

Original languageEnglish
Pages (from-to)163-167
Number of pages5
JournalInternational Journal of Cancer
Volume45
Issue number1
DOIs
StatePublished - 15 Jan 1990

Fingerprint

Dive into the research topics of 'Murine spontaneous T‐cell leukemia constitutively expressing IL‐2 receptor—a model for human T‐cell malignancies expressing IL‐2 receptor'. Together they form a unique fingerprint.

Cite this